Drug information of Daclatasvir

Daclatasvir

Drug group: NS5A Inhibitor

Daclatasvir is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. Daclatasvir is used to treat genotype 3 chronic hepatitis C in adults without cirrhosis. This medicine is given together with another drug called sofosbuvir.

Mechanism of effect

Daclatasvir binds to the N-terminus within Domain 1 of HCV nonstructural protein 5A (NS5A) and inhibits viral RNA replication and virion assembly.

Pharmacodynamic

Daclatasvir does not appear to prolong the QT interval even when given at 3 times the maximum recommended dose

Pharmacokinetics

Studies demonstrated that peak plasma concentrations typically occurred within 2 hours after administration Daclatasvir is estimated to be 99% protein bound. Metabolism:Primarily via CYP3A. Excretion:Feces (88%, 53% unchanged); urine (6.6%, primarily unchanged). Half-Life Elimination:12 to 15 hours.

Dosage

Dosing: Adult Chronic hepatitis C (genotype 1 or 3): Oral: Genotype 1: Without cirrhosis or with compensated (Child-Pugh class A) cirrhosis: 60 mg once daily with concomitant sofosbuvir for 12weeks. Genotype 3: Without cirrhosis: 60 mg once daily with concomitant sofosbuvir for 12 weeks

Alerts

1-Discontinue daclatasvir if other antihepaciviral therapy is permanently discontinued. Not indicated as monotherapy. 2-Bradycardia: When used in combination with sofosbuvir and amiodarone, symptomatic bradycardia (eg, near-fainting, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion, or memory problems) has been reported 3-Disease-related concerns:Cardiovascular disease,Hepatic disease

Points of recommendation

1-Oral: Administer with or without food. 2-During therapy: CBC, serum creatinine, calculated GFR, hepatic function panel (after 4 weeks of therapy and as clinically indicated); quantitative HCV viral load testing (after 4 weeks of therapy and at 12 weeks after completion of therapy). If quantitative HCV viral load is detectable at treatment week 4, repeat testing is recommended after 2 additional weeks of treatment (treatment week 6).

Pregnancy level

X


Ask a Pharmacist


User's questions
    No comments yet.